Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities
Biomed Pharmacother. 2024 Apr 24;175:116615. doi: 10.1016/j.biopha.2024.116615. Online ahead of print.ABSTRACTEstrogens play a critical role in the initiation and progression of breast cancer. Estrogen receptor (ER)α, ERβ, and G protein-coupled estrogen receptor are the primary receptors for estrogen in breast cancer. These receptors are mainly activated by binding with estrogens. The crosstalk between ERs and membrane growth factor receptors creates additional pathways that amplify the effects of their ligands and promote tumor growth. This crosstalk may cause endocrine therapy resistance in ERα-positive breast cancer....
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 25, 2024 Category: Drugs & Pharmacology Authors: Shunchao Yan Jiale Ji Zhijie Zhang Murshid Imam Hong Chen Duo Zhang Jinpeng Wang Source Type: research
Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities
Biomed Pharmacother. 2024 Apr 24;175:116615. doi: 10.1016/j.biopha.2024.116615. Online ahead of print.ABSTRACTEstrogens play a critical role in the initiation and progression of breast cancer. Estrogen receptor (ER)α, ERβ, and G protein-coupled estrogen receptor are the primary receptors for estrogen in breast cancer. These receptors are mainly activated by binding with estrogens. The crosstalk between ERs and membrane growth factor receptors creates additional pathways that amplify the effects of their ligands and promote tumor growth. This crosstalk may cause endocrine therapy resistance in ERα-positive breast cancer....
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 25, 2024 Category: Drugs & Pharmacology Authors: Shunchao Yan Jiale Ji Zhijie Zhang Murshid Imam Hong Chen Duo Zhang Jinpeng Wang Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Cancer Research - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Cancer Research - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Genitourinary Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane
ConclusionTo the best of our knowledge, we present here for the first time a comprehensive and direct head-to-head, intra-patient-cross-over comparison of the aromatase inhibitor letrozole and the aromatase inactivator exemestane concerning their ability to suppress serum estrogen levels in vivo. All in all, our results clearly demonstrate that letrozole therapy results in a more profound suppression of serum E1 and E2 levels compared to exemestane. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 23, 2024 Category: Cancer & Oncology Source Type: research
Estrogen receptor alpha mutations, truncations, heterodimers, and therapies
Endocrinology. 2024 Apr 21:bqae051. doi: 10.1210/endocr/bqae051. Online ahead of print.ABSTRACTAnnual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with widespread adoption of hormone therapies that target estrogen receptor alpha (ERα), the prominent nuclear receptor expressed in ∼80% of BCa. However, up to ∼50% of ER + patients with high-risk disease experience post endocrine therapy relapse and metastasis to distant organs. The vast majority of BCa mortality occurs in this setting, highlighting the inadequacy of current therapies. Genomic abnormalities to ESR1, the gene encoding ERα, e...
Source: Endocrinology - April 21, 2024 Category: Endocrinology Authors: Govinda R Hancock Jason Gertz Rinath Jeselsohn Sean W Fanning Source Type: research
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study
CONCLUSION: The addition of palbociclib to ET was effective for treating HR+/HER2- ABC in Japanese routine clinical practice.PMID:38642245 | DOI:10.1007/s12282-024-01575-5 (Source: Breast Cancer)
Source: Breast Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Tetsuhiro Yoshinami Shigenori E Nagai Masaya Hattori Takuho Okamura Kenichi Watanabe Takahiro Nakayama Hiroko Masuda Michiko Tsuneizumi Daisuke Takabatake Michiko Harao Hiroshi Yoshino Natsuko Mori Hiroyuki Yasojima Chiya Oshiro Madoka Iwase Miki Yamaguch Source Type: research
PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ER α stability
In conclusion, these data suggest that PFKFB3 is identified as an adverse prognosis factor for ER-positive breast cancer and plays a previously unrecognized role in the regulation of ERα stability and activity. Our results further explores an effective approach to improve fulvestrant sensitivity through the early combination with a PFKFB3 inhibitor.PMID:38640982 | DOI:10.1016/j.cellsig.2024.111184 (Source: Cellular Signalling)
Source: Cellular Signalling - April 19, 2024 Category: Cytology Authors: Wenzhi Jia Qianyun Wu Mengqin Shen Xiaofeng Yu Shuxian An Li Zhao Gang Huang Jianjun Liu Source Type: research
Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors
British Journal of Cancer, Published online: 18 April 2024; doi:10.1038/s41416-024-02680-0Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors (Source: British Journal of Cancer)
Source: British Journal of Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Ching-Yuan Chang Bobby L. Jones Juan M. Hincapie-Castillo Haesuk Park Coy D. Heldermon Vakaramoko Diaby Debbie L. Wilson Wei-Hsuan Lo-Ciganic Source Type: research
